Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed.
Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. ET on Dec. 24, 2021.
Today, Novo Nordisk has acquired all outstanding shares of Dicerna’s common stock at a price of $38.25 per share without interest and less any applicable tax withholding.
Novo Nordisk has been advised by the depositary for the tender offer that almost 65 million shares of Dicerna’s common stock were validly tendered and not validly withdrawn in the tender offer as of the expiration fo the tender offer at 5 p.m. ET on Dec. 27, 2021, representing approximately 82.6% of the total number of shares of Dicerna’s common stock outstanding.
The company completed the acquisition of Dicerna through a merger of its wholly-owned subsidiary with and into Dicerna in which all shares not tendered into the offer were canceled and converted into the right to receive cash equal to the $38.25 per share offer price.
Dicerna has now become a wholly-owned subsidiary of Novo Nordisk and its common stock will no longer be listed or traded on the Nasdaq market.
